Application of flow cytometric cell cycle analysis to the assessment of condition and growth in larvae of a freshwater teleost Galaxias olidus

2000 ◽  
Vol 57 (4) ◽  
pp. 732-741 ◽  
Author(s):  
Don Bromhead ◽  
John Kalish ◽  
Paul Waring

Through its ability to measure cell DNA content, flow cytometric analysis (FCA) is a technique capable of accurately assessing the position of cells in the cell cycle. Using FCA to measure the proportion of dividing and nondividing cells, an index was created that allows the amount of cell division within larval fish tissues to be quantified. To assess the suitability of the cell division index (CDI) as an indicator of growth and condition in fish larvae, analyses were divided into four parts. These examined the effects of temperature, nutrition, time of day, and geographic location on the CDI of brain tissue from Galaxias olidus larvae. The index was sensitive to, firstly, differences in the brain CDI of larvae reared at 12 and 20°C and, secondly, to significant fluctuations in mean brain CDI from larvae sampled over 24 h. FCA also revealed significant differences in the CDI of starving and fed larvae. Overall, this study indicates that FCA may be suitable as an indicator of growth and condition in both laboratory-reared and wild fish larvae.

2016 ◽  
Vol 36 (10) ◽  
pp. 1059-1070 ◽  
Author(s):  
MBO Chagas ◽  
NCC Cordeiro ◽  
KMR Marques ◽  
MG Rocha Pitta ◽  
MJBM Rêgo ◽  
...  

A series of new thiazacridine agents were synthesized and evaluated as antitumor agents, in terms of not only their cytotoxicity but also their selectivity. The cytotoxicity assay confirmed that all compounds showed cytotoxic activity and selectivity. The new compound, 3-acridin-9-ylmethyl-5-(5-bromo-1 H-indol-3-ylmethylene)-thiazolidine-2,4-dione (LPSF/AA29 – 7a), proved to be the most promising compound as it presents lower half-maximal inhibitory concentration (IC50) values (ranging from 0.25 to 68.03 µM) depending on cell lineage. In HepG2 cells, the lowest IC50 value was exhibited by 3-acridin-9-ylmethyl-5-(4-piperidin-1-yl-benzylidene)-thiazolidine-2,4-dione (LPSF/AA36 – 7b; 46.95 µM). None of the synthesized compounds showed cytotoxic activity against normal cells (IC50 > 100 µM). The mechanism of death induction and cell cycle effects was also evaluated. Flow cytometric analysis revealed that the compounds LPSF/AA29 – 7a and LPSF/AA36 – 7b significantly increased the percentage of apoptotic cells and induced G2/M arrest in the cell cycle progression. Therefore, these new thiazacridine derivatives constitute promising antitumor agents whose cytotoxicity and selectivity properties indicate they have potential to contribute to or serve as a basis for the development of new cancer drugs in the future.


2011 ◽  
Vol 84 (3) ◽  
pp. 355-359 ◽  
Author(s):  
Borislava I. Boteva ◽  
Rada M. Mateva ◽  
Ivan A. Iliev ◽  
Galina A. Gorneva

Science ◽  
1983 ◽  
Vol 220 (4601) ◽  
pp. 1049-1051 ◽  
Author(s):  
D. W. GALBRAITH ◽  
K. R. HARKINS ◽  
J. M. MADDOX ◽  
N. M. AYRES ◽  
D. P. SHARMA ◽  
...  

2019 ◽  
Vol 21 (Supplement_6) ◽  
pp. vi94-vi94
Author(s):  
Taylor Dismuke ◽  
Chaemin Lim ◽  
Timothy Gershon

Abstract CDK4/6 inhibition is a promising therapy for medulloblastoma, one of the most common malignant pediatric brain tumors. To improve pharmacokinetics, we developed a polyoxazoline nanoparticle-encapsulated formulation of the FDA-approved CDK4/6 inhibitor palbociclib (POx-palbo). We then administered POx-palbo to transgenic medulloblastoma-prone GFAP-Cre/SmoM2 mice, to determine the efficacy and mechanisms of action and resistance. We found that POx-palbo slowed tumor progression, but consistently failed to be curative. Further analysis showed that while CDK4/6 inhibition acutely blocked G1 cells from re-entering the cell cycle, this effect wore off within hours of drug administration. However, flow cytometric analysis of EdU uptake hours after palbociclib demonstrated aberrant S-phase with reduced rate of DNA synthesis. This POx-palbociclib-induced alteration of S-phase progression seems to remain true at later time points even when we observed that palbociclib G1/S inhibition began to decrease. Based on these data, we propose that the combinational therapy of POx-palbociclib and S-phase targeting agents will further improve treatment. Faulty tumor cell cycle progression in the presence of Pox-palbociclib may give increased window to target the S-phase for irreversible cell-cycle exit.


1993 ◽  
Vol 9 (1) ◽  
pp. 77-83 ◽  
Author(s):  
Suzanne M. Morris ◽  
Olen E. Domon ◽  
Lynda J. McGarrity ◽  
Anane Aidoo ◽  
Ralph L. Kodell ◽  
...  

PLoS ONE ◽  
2018 ◽  
Vol 13 (1) ◽  
pp. e0191178 ◽  
Author(s):  
Erin J. Vanzyl ◽  
Kayleigh R. C. Rick ◽  
Alex B. Blackmore ◽  
Erin M. MacFarlane ◽  
Bruce C. McKay

Sign in / Sign up

Export Citation Format

Share Document